✦ LIBER ✦

Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors

✍ Scribed by Iñaki F. Trocóniz, Josep-María Cendrós, Elena Soto…

Book ID: 120776480
Publisher: Springer
Year: 2012
Tongue: English
Weight: 510 KB
Volume: 70
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-012-1906-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I, dose-finding and pharmacokine

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors

✍ Noboru Yamamoto; Hiroshi Nokihara; Yasuhide Yamada; Yasushi Goto; Maki Tanioka; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB

Phase I Pharmacokinetic and Pharmacodyna

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

✍ Paz-Ares, L. G.; Gomez-Roca, C.; Delord, J.-P.; Cervantes, A.; Markman, B.; Corr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB

282 POSTER Preliminary results of a Phas

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

✍ P. Schöffski; H. Dumez; S.F. Jones; C. Fowst; P. Gerletti; H. Xu; J. Jakubczak; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB

346 POSTER CBP501, a novel cell cycle G2

346 POSTER CBP501, a novel cell cycle G2 checkpoint abrogator. Preliminary results of the initial phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study in patients (pts) with advanced solid tumors

✍ M.S. Gordon; J.P. Eder; D.S. Mendelson; E. Wasserman; W. Sutherland; T. Kawabe; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB